reported that S100A2‐3, S100A5, S100A7‐9, S100A14‐16, and S100P were significantly higher in BLCA tissues using real‐time PCR.[16] The comprehensive roles of S100 proteins in the TME and immunotherapy remain unclear, especially in BLCA. This evidence concerns the gene S100A5 and bladder transitional cell carcinoma.